MAIA Bio Appoints New CMO, Adds Directors
Ticker: MAIA · Form: 8-K · Filed: Apr 2, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $250,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
TL;DR
MAIA Bio beefs up leadership with new CMO and board members.
AI Summary
MAIA Biotechnology, Inc. announced on April 1, 2024, the appointment of Dr. Joseph M. Rubinfeld as Chief Medical Officer and the election of Dr. Rubinfeld and Ms. Karen L. Smith to its Board of Directors. The company also disclosed compensatory arrangements for its named executive officers, though specific dollar amounts for these arrangements were not detailed in this filing.
Why It Matters
The appointment of a new Chief Medical Officer and board members suggests a strategic shift or strengthening of leadership within MAIA Biotechnology, potentially impacting its drug development and clinical trial strategies.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can indicate internal shifts that may affect future company performance and strategy.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- Dr. Joseph M. Rubinfeld (person) — Appointed Chief Medical Officer and elected to Board of Directors
- Ms. Karen L. Smith (person) — Elected to Board of Directors
- April 1, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for MAIA Biotechnology, Inc.?
Dr. Joseph M. Rubinfeld has been appointed as the new Chief Medical Officer for MAIA Biotechnology, Inc.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on April 1, 2024.
Besides the new CMO, who else was elected to the Board of Directors?
Ms. Karen L. Smith was also elected to the Board of Directors.
What is the principal executive office address for MAIA Biotechnology, Inc.?
The principal executive office address is 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the SIC code for MAIA Biotechnology, Inc.?
The Standard Industrial Classification (SIC) code for MAIA Biotechnology, Inc. is 2834, Pharmaceutical Preparations.
Filing Stats: 399 words · 2 min read · ~1 pages · Grade level 13.8 · Accepted 2024-04-02 16:10:55
Key Financial Figures
- $250,000 — Employment Agreement") was increased to $250,000 and the target Annual Bonus under Secti
Filing Documents
- d818590d8k.htm (8-K) — 21KB
- 0001193125-24-084756.txt ( ) — 143KB
- maia-20240401.xsd (EX-101.SCH) — 3KB
- maia-20240401_lab.xml (EX-101.LAB) — 18KB
- maia-20240401_pre.xml (EX-101.PRE) — 11KB
- d818590d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: April 2, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 3